Nuvalent Inc Ordinary Shares - Class A NUVL 深 滬
等待開盤 09-25 09:30:00 美东时间
79.54
-1.540
-1.90%
華盛通- 最 高82.81
- 今 開81.07
- 成交量 32.65万股
- 最 低 79.021
- 昨 收 81.08
- 總市值 57.35亿
- 52周最高 106.32
- 市盈率 靜 --
- 換手率 0.45%
- 52周最低 55.535
- 委 比 -76.61%
- 總股本 7210.48万
- 歷史最高 113.51
- 量 比 0.74
- 振 幅 4.67%
- 歷史最低 7.09
- 每 手 1
- 風險率 9.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuvalent Completes New Drug Application Submission
The latest update is out from Nuvalent ( ($NUVL) ). On September 22, 2025, Nuva...
09-22 18:58
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Raymond James Initiates Coverage On Nuvalent with Outperform Rating, Announces Price Target of $105
Raymond James analyst Chris Raymond initiates coverage on Nuvalent (NASDAQ:NUVL) with a Outperform rating and announces Price Target of $105.
09-04 00:51
Piper Sandler initiates coverage of oncology companies
Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for cr...
08-19 23:17
Piper Sandler Initiates Coverage On Nuvalent with Overweight Rating, Announces Price Target of $112
Piper Sandler analyst Kelsey Goodwin initiates coverage on Nuvalent (NASDAQ:NUVL) with a Overweight rating and announces Price Target of $112.
08-19 19:50
Nuvalent shares are trading lower after the company reported worse-than-expected Q2 financial results.
Nuvalent shares are trading lower after the company reported worse-than-expecte...
08-08 00:32
Nuvalent Q2 EPS $(1.39) Misses $(1.22) Estimate
Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.22) by 13.65 percent. This is a 57.95 percent decrease over losses of $(0.88) per share from the
08-07 18:40
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial
Nuvalent ( ($NUVL) ) has issued an update. On July 21, 2025, Nuvalent, Inc. ann...
07-21 18:58
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
